Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
mHag-loaded donor dendritic cell vaccination plus donor lymphocyte infusion after allogeneic stem cell transplantation
NL-OMON37500Phase 2Active, not recruiting
- Sponsor
- University Medical Center Utrecht
- Start
- May 2014
- Modality
- Cell Therapies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of donor lymphocytes in hematopoietic malignancies, sponsored by University Medical Center Utrecht. Primary endpoints: Safety, Graft-versus-host disease occurrence and 1 more. Started May 2014; status: active, not recruiting.
02
Drugs
donor lymphocytes
03
Conditions
hematopoietic malignancies
Beyond the preview
Go deeper on NL-OMON37500.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON37500.